
Verici Dx plc
("Verici Dx" or the "Company")
Result of General Meeting
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the General Meeting ("GM") held earlier today, all resolutions, as set out in the GM notice published on 9 May 2025, were duly passed on a poll. Resolution 1 was passed as an ordinary resolution and resolution 2 was passed as a special resolution.
The voting results of the GM were as follows:
|
|
In Favour |
Against |
Withheld |
||
|
Resolution |
Votes |
% |
Votes |
% |
Votes |
|
1 |
112,453,134 |
99.96 |
47,616 |
0.04 |
23,820 |
|
2 |
112,380,881 |
99.89 |
119,738 |
0.11 |
23,951 |
|
Verici Dx plc
|
||
|
Sara Barrington, CEO |
Via Walbrook PR |
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Phil Davies / Sam Butcher |
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com |
|
|
Alice Woodings / Paul McManus |
Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893 |
|
|
|
|
|